Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms - Vieri, Margherita; Tharmapalan, Vithurithra; Kalmer, Milena; Baumeister, Julian; Nikolić, Miloš; Schnitker, Matthis; Kirschner, Martin; Flosdorf, Niclas; de Toledo, Marcelo A. S.; Zenke, Martin; Koschmieder, Steffen; Brümmendorf, Tim H.; et al. (medRxiv, 2023)
Myeloproliferative neoplasms (MPNs) are caused by somatic driver mutations, such as JAK2V617F, which might also affect cellular aging and senescence. Here, we analyzed the heterogeneity of aging in MPN patients and if this can be used to specifically target malignant cells. The mean epigenetic age was significantly accelerated in 129 MPN patients across all disease-entities, whereas premature telomere attrition was particularly observed in primary myelofibrosis. Overall, accelerated cellular aging correlated with JAK2V617F allele frequency and was more pronounced in colony forming cells with JAK2V617F as compared to JAK2 wild- type colonies. JAK2V617F mutation did not evoke clear acceleration of aging in syngeneic iPSC models upon short-term hematopoietic differentiation. On the other hand, a murine Jak2V617F model revealed epigenetic age-acceleration that therefore appears as sequel of disease progression. To investigate if the malignant clone might be targeted, we tested eight senolytic compounds, of which JQ1 and piperlongumine showed a reduction in allele burden and an increase in telomere length. Notably, treatment with the telomerase inhibitor BIBR-1532 reduced mutated colonies, particularly in patients with preexisting short telomeres. Our results indicate that cellular aging is accelerated in malignant MPN clones and this can provide a target for treatment with senolytic drugs or telomerase inhibitors.Competing Interest StatementW.W. and V.T. are involved in Cygenia GmbH (www.cygenia.com), which can provide services for DNA methylation analysis to other scientists. T.H.B. and F.B. have a scientific collaboration with Repeat Dx (Vancouver, Canada). S.K. reports research funding, advisory board honoraria, honoraria, and other financial support (e.g., travel support) from Janssen and Geron; and a patent for a BET inhibitor at RWTH Aachen University. All other authors declare no competing financial interests.Funding StatementThis work was supported by the Flow Cytometry Facility, a core facility of the Interdisciplinary Center for Clinical Research (IZKF) Aachen within the Faculty of Medicine at RWTH Aachen University. We thank Lichterzellen (www.lichterzellen.de) and AA/PNH e.V. for their initiative, enthusiasm and continued support to T.H.B and M.V.; M.A.S.T was funded by CAPES-Alexander von Humboldt postdoctoral fellowship (99999.001703/2014-05) and donation by U. Lehmann. This work was supported by funds from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) within CRU344 'Untangling and Targeting Mechanisms of Myelofibrosis in Myeloproliferative Neoplasms' (WA 1706/12-1 and WA1706/14-1; KO2155/7-1; BR1782/5-1; ZE432/10-1) and KO2155/6-1; by Deutsche Krebshilfe (TRACK-AML); and the ForTra gGmbH for Forschungstransfer der Else Kroener-Fresenius-Stiftung.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All samples were obtained after informed and written consent in accordance with the Declaration of Helsinki and the local ethics committee of RWTH Aachen University (EK 041/15, EK 206/09 and EK 127/12) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe datasets used and/or analysed in this current study are available from the corresponding author on reasonable request.